EVALUATION OF MULTIPLE HEMOSTATIC PARAMETERS FOLLOWING DOSING OF RECOMBINANT

重组给药后多个止血参数的评估

• 批准号: 8166551
• 负责人: Donald Fitzpatrick Brophy
• 金额: $ 0.02万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166551
• 关键词: Biological Assay; Blood Coagulation Factor VII; Blood Platelets; Coagulation Process; Computer Retrieval of Information on Scientific Projects Database; Dose; Evaluation; Factor VIII; Fibrin fragment D; Funding; Generations; Grant; Hemostatic Agents; In Vitro; Institution; Patients; Recombinants; Research; Research Personnel; Resources; Source; Thrombelastography; Thrombin; Time; United States National Institutes of Health; antithrombin III-protease complex; inhibitor/antagonist; prothrombin fragment 1.2

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypothesis: Following dosing of recombinant Factor Vila 90 mcg/kg in hemophiliacs, platelet contractile force (PC F), clot elastic modulus (CEM) and thrombin generation time (TGT) normalize. These parameters will change comparably to the following established clotting parameters: Thromboelastography (TEG), Rotational Thromboelastography (ROTEG), in vitro thrombin generation, thrombin-antithrombin complex, Prothrombin Fragment 1.2, Factor VII activity and D-dimer. Specific Aims: a. Document baseline TGT, PCF and CEM abnormalities in hemophiliacs with and without spontaneous factor VIII inhibitors. Secondly, document clotting deficiencies utilizing the TEG4!> and ROTEG4!> clotting parameters as well as assays detecting thrombin generation, TAT, Prothrombin Fragment 1.2, Factor 7 activity and D-dimer. b. Establish the extent by which TGT, PCF and CEM normalize in the above patients following the administration of rFVlla 90 mcg/kg. Secondly, document the extent by which clotting deficiencies normalize utilizing the TEG4!> and ROTEG4!> clotting parameters, as well as assays detecting thrombin generation, TAT, Prothrombin Fragment 1.2, Factor 7 activity and D-dimer.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 假设：重组因子VILA VILA 90 MCG/kg剂量后，血小板收缩力（PC F），凝块弹性模量（CEM）（CEM）和凝血酶生成时间（TGT）正常化。这些参数将与以下已建立的凝血参数相比变化：血栓射击（TEG），旋转血栓射击学（ROTEG），体外凝血酶生成，脑栓蛋白 - 抗凝血酶复合物，凝血酶原片段，凝血酶原片段1.2，因子VII因子VII活性和D-二聚体。 具体目的： 一个。记录基线TGT，PCF和CEM异常，具有和不具有自发因子VIII抑制剂。其次，利用TEG4！>和Roteg4！>凝血参数的文档凝结缺陷以及检测凝血酶生成，TAT，凝血酶蛋白片段1.2，因子7活动和D-二聚体的测定。 b。在施用RFVLLA 90 MCG/kg之后，确定上述患者中TGT，PCF和CEM正常化的程度。其次，记录了使用TEG4！>和Roteg4！>凝血参数正常化的凝结缺陷的程度，以及检测凝血酶生成，TAT，凝血酶原片段1.2，因子7活动和D-二聚体的测定。